程序性死亡受体配体1表达与肾细胞癌患者临床特征及预后的关系  

Relationship between the expression of programmed cell death 1 ligand 1 and the clinical features and prognosis of patients with renal cell carcinoma

作　　者：尚杰 周文艳 惠红岩[3] 苏蔚[1] 狄文玉[1] SHANG Jie;ZHOU Wenyan;HUI Hongyan;SU Wei;DI Wenyu(Department of Pathology,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,He’nan,China;Department of Ultrasound Medicine,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,He’nan,China;Department of Clinical Pharmacy,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,He’nan,China)

机构地区：[1]新乡医学院第一附属医院病理科,河南新乡4531000 [2]新乡医学院第一附属医院超声医学科,河南新乡4531000 [3]新乡医学院第一附属医院临床药学学部,河南新乡4531000

出　　处：《癌症进展》2024年第17期1908-1911,共4页Oncology Progress

摘　　要：目的探讨程序性死亡受体配体1(PD-L1)表达与肾细胞癌(RCC)患者临床特征及预后的关系。方法收集120例RCC患者的病历资料,比较不同病理类型及临床特征RCC患者PD-L1表达情况,并采用Cox回归模型分析RCC患者PD-L1表达情况的影响因素。对所有患者随访1年,分析不同PD-L1表达情况RCC患者的生存情况。结果120例RCC患者中,PD-L1阳性64例,阴性56例,阳性表达率为53.33%。不同病理类型RCC患者PD-L1阳性表达率比较,差异无统计学意义(P﹥0.05)。不同年龄、临床分期RCC患者PD-L1阳性表达率比较,差异均有统计学意义(P﹤0.05)。Cox回归分析结果显示,年龄﹥60岁、临床分期Ⅲ~Ⅳ期均为RCC患者PD-L1阳性表达的危险因素(P﹤0.05)。PD-L1阴性RCC患者的生存率高于PD-L1阳性患者,差异有统计学意义(P﹤0.05)。结论PD-L1表达情况与RCC患者的年龄和临床分期有关。PD-L1阳性RCC患者的生存率较低。年龄﹥60岁、临床分期Ⅲ~Ⅳ期均为RCC患者PD-L1阳性表达的危险因素。Objective To investigate the relationship between the expression of programmed cell death 1 ligand 1(PD-L1)and the clinical features and prognosis of patients with renal cell carcinoma(RCC).Method The medical records of 120 patients with RCC were collected,the expression of PD-L1 in RCC patients with different pathological types and clinical features were compared,the influencing factors of PD-L1 expression in RCC patients were analyzed by Cox regression model.All patients were followed up for one year,and the survival of RCC patients with different PD-L1 expression was analyzed.Result Among 120 RCC patients,64 cases were positive for PD-L1 and 56 cases were negative,with a positive expression rate of 53.33%.There was no significant difference in the positive expression rate of PD-L1 among RCC patients with different pathological types(P>0.05).The positive expression rates of PD-L1 in RCC patients with different ages and clinical stages were compared,and the differences were statistically significant(P<0.05).Cox regression analysis showed that age>60 years old and clinical stage III-IV were risk factors for positive expression of PD-L1 in RCC patients(P<0.05).The survival rate of RCC patients with PD-L1 negative expression was higher than that of patients with PD-L1 positive expression,and the difference was statistically significant(P<0.05).Conclusion The expression of PD-L1 is related to the age and clinical stage of RCC patients.The survival rate of RCC patients with PD-L1 positive expression is lower.Age>60 years old and clinical stage III-IV are risk factors for positive expression of PDL1 in RCC patients.

关 键 词：肾细胞癌 程序性死亡受体配体1 临床特征 预后 

分 类 号：R737.11[医药卫生—肿瘤]